EVENTS|NEWS|CONTACT|DONATE

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Read Our Newsletter

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Day

August 7, 2020

Biosimilar Trastuzumab Effective in Triplet Regimen for Gastric Cancer

A biosimilar version of Herceptin taken in combination with chemo and the immune-boosting drug Keytruda reduced tumor size in a clinical trial...

Social Media

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Categories

Foundation News
Press Releases
Research News

Tags

adenocarcenoma advanced stage alcohol antibody biomarker blood chemoradiotherapy chemotherapy clinical trial clinical trials detection drugs endoscopy Epstein-Barr esophagogastric FDA gastrectomy gastric cancer registry gastroesophageal genes heartburn helicobacter pylori HER2 immunotherapy keytruda lonsurf metastatic nutrition peritoneal postoperative prevention proton pump inhibitor recovery recurrence research risk screening side-effects studies surgery survival treatment tumor virus women

Gastric Cancer Foundation

Tax ID 27-2978173

info@gastriccancer.org

PO Box 338
Millbrae, CA 94030

For Deliveries:
Gastric Cancer Foundation
501 Broadway, #338
Millbrae, CA 94030-1907

Site Map

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Social Feed

Gastric Cancer Foundation

1 month ago

As a founding supporter of Test Your Biomarkers , a national campaign to inform people about the importance of biomarker testing in the treatment of stomach cancer, we are proud to offer patients another resource to learn more about treatment options. Learn more at testyourbiomarkers.org ... See MoreSee Less

testyourbiomarkers.org

Biomarkers are the key to treating stomach cancer. Test first. Because the best treatment for your stomach cancer can be individualized.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 month ago

New study published in Nature finds that PIEZO2, a protein linked to nerve responses, is now identified as a key predictor for gastric cancer outcomes. High PIEZO2 levels mean poorer survival, and its connection with immune cells suggests potential as an immunotherapy target. ... See MoreSee Less

PIEZO2 expression is an independent biomarker prognostic for gastric cancer and represents a potential therapeutic target - Scientific Reports

www.nature.com

Gastric cancer (GC) is one of the most prevalent malignant tumors of the gastrointestinal system in the globe. The effect of PIEZO2 on the immune function and pathological features of gastric cancer r...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 month ago

We partnered with Smart Patients to create an online community for patients and families affected by gastric cancer to support each other. Join the conversation and unlock resources to help you on your journey. Visit smartpatients.com/partners/gastric-cancer-foundation ... See MoreSee Less

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 month ago

Research published in Targeted Oncology suggests that using Nivolumab (Opdivo) alongside chemotherapy reveals a 29% reduced risk of death and a 3.3-month survival boost in HER2-negative esophageal/gastric cancer patients with a PD-L1 combined positive score (CPS) greater than 5. Noteworthy progress in treatment insights. ... See MoreSee Less

Nivolumab Plus Chemotherapy Demonstrates Superior OS in Esophageal/Gastric Cancer

www.targetedonc.com

At 12 months, patients in the experimental arm showed OS rates of 14.4% compared with 11.1% for patients receiving chemotherapy alone in the phase 3, open-label CheckMate649 study.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 month ago

Researchers from Jiangsu University, in an article in the Journal of Translational Medicine, unveil CHAF1A as a potential immunotherapy biomarker for Epstein-Barr virus-positive gastric cancer. It predicts overall survival, correlates with immune cell infiltration, and enhances stratification when combined with existing markers. ... See MoreSee Less

A novel biomarker associated with EBV infection improves response prediction of immunotherapy in gastric cancer - Journal of Translational Medicine

link.springer.com

Background Novel biomarkers are required in gastric cancer (GC) treated by immunotherapy. Epstein-Barr virus (EBV) infection induces an immune-active tumor microenvironment, while its association with...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Subscribe to Our Newsletter

We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.

© 2024 Gastric Cancer Foundation. All Rights Reserved.

EVENTS | NEWS | CONTACT | DONATE

X